Vamorolone is a Small Molecule owned by Santhera Pharmaceuticals, and is involved in 8 clinical trials, of which 5 were completed, and 3 are ongoing.
Vamorolone acts as NR3C1 agonist. The drug candidate binds to the glucocorticoid receptor and shows a wide range of inhibitory activities on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. It binds to the glucocorticoid receptor (GR) and the drug-receptor complex translocates to the nucleus and acts as transcription factor for target gene expression.
The revenue for Vamorolone is expected to reach a total of $5.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vamorolone NPV Report.
Vamorolone (VBP-15) is under development for the treatment of mild or moderately active ulcerative colitis, Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, asthma, chronic obstructive pulmonary disorder, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, ANCA-associated vasculitis, juvenile dermatomyositis, calpain 3 deficiency (LGMD2A), limb girdle muscular dystrophy type 2B (LGMD2B) and was under development for the treatment of sickle cell anemia, cystic fibrosis and systemic juvenile idiopathic arthritis (SJIA). It is administered orally as suspension. Vamorolone is a dissociative delta-9, 11 glucocorticoid analogue, a steroidal drug. It targets NR3C1.
Santhera Pharmaceuticals Overview
Santhera Pharmaceuticals (Santhera) develops and markets novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. The company specifically focuses on the area of neuromuscular and ophthalmological conditions. The company’s lead product candidate, Raxone is developed for the treatment of Leber’s hereditary optic neuropathy (LHON) and is approved by the European Marketing Authorization. Raxone is investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santhera’s pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. It operates through its subsidiaries in Switzerland, Liechtenstein, Germany, Canada, the UK, Italy, the Netherlands, and the US. Santhera is headquartered in Pratteln, Switzerland.
The company reported revenues of (Swiss Francs) CHF1.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CHF15 million in FY2020. The operating loss of the company was CHF56.9 million in FY2021, compared to an operating loss of CHF53.1 million in FY2020. The net loss of the company was CHF55.5 million in FY2021, compared to a net loss of CHF67.7 million in FY2020.
Quick View – Vamorolone
|Highest Development Stage|